Literature DB >> 23009739

Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy.

Kay Greveson1, James Goodhand, Santino Capocci, Sue Woodward, Charles Murray, Ian Cropley, Mark Hamilton, Marc Lipman.   

Abstract

BACKGROUND AND AIMS: Testing for LTBI is recommended prior to anti-TNFα agents. This includes an assessment of TB risk factors, chest radiograph, and interferon-gamma release assay alone or with concurrent Tuberculin skin testing. Here we review our experience and cost-effectiveness of using T-SPOT.TB IGRA to detect mycobacterial infection in patients with IBD suitable for anti-TNFα therapy.
METHODS: This was a single-centre, retrospective review and economic evaluation (compared to British Thoracic Society guidance) of 125 adult IBD patients (90 anti-TNFα naïve, 35 established on anti-TNFα) tested for LTBI using T-SPOT.TB IGRA.
RESULTS: All subjects had normal chest radiographs and no clinical evidence for TB. 109 (87%) were BCG vaccinated. 27 (22%) of all patients tested were not using immunomodulation at the time of testing. 66 (53%) were taking thiopurines, 22 (18%)corticosteroids, and 35 (28%) anti-TNFα agents. One hundred twenty two (98%) had a negative IGRA result, two (2%) had positive results, and one (1%) had an indeterminate IGRA. A strategy using IGRA to guide TB preventative treatment produced cost savings of £10.79 per person compared to the BTS guidance. Eighty eight percent of the anti-TNFα naïve group have subsequently received treatment with either infliximab or adalimumab (median follow-up of 24 months, IQR 18-30) with no cases of TB disease occurring.
CONCLUSIONS: The use of a simple screening protocol for LTBI incorporating T-SPOT.TB IGRA in place of TST in a largely BCG vaccinated population, many using immunomodulatory agents, appears to work well and is a cost-effective strategy in our IBD service.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23009739     DOI: 10.1016/j.crohns.2012.08.010

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  7 in total

1.  Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?

Authors:  M G Johnson; R W Bialas; R P Hall; J E Stout
Journal:  J Dermatolog Treat       Date:  2015-12-10       Impact factor: 3.359

Review 2.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 3.  Managing acute severe ulcerative colitis in the hosptialised setting.

Authors:  David McClements; Chris Probert
Journal:  Frontline Gastroenterol       Date:  2014-07-08

Review 4.  Diagnosis and Management of Latent Tuberculosis Infection.

Authors:  Laura Muñoz; Helen R Stagg; Ibrahim Abubakar
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-08       Impact factor: 6.915

5.  Unique Chemokine Profiles of Lung Tissues Distinguish Post-chemotherapeutic Persistent and Chronic Tuberculosis in a Mouse Model.

Authors:  Soomin Park; Seung-Hun Baek; Sang-Nae Cho; Young-Saeng Jang; Ahreum Kim; In-Hong Choi
Journal:  Front Cell Infect Microbiol       Date:  2017-07-13       Impact factor: 5.293

6.  High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population.

Authors:  Robert W Aldridge; Andrew C Hayward; Sara Hemming; Susan K Yates; Gloria Ferenando; Lucia Possas; Elizabeth Garber; John M Watson; Anna Maria Geretti; Timothy Daniel McHugh; Marc Lipman; Alistair Story
Journal:  Thorax       Date:  2018-01-29       Impact factor: 9.139

Review 7.  Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Chan Hyuk Park; Jung Ho Park; Yoon Suk Jung
Journal:  J Pers Med       Date:  2022-03-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.